Wall Street analyst estimates for Immunome, Inc. (IMNM): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2027E | $48.7M | $10.5M – $90.2M | -$2.49 | 11 |
| 2028E | $183M | $72.1M – $321M | -$1.63 | 10 |
Figures in USD · consensus as of November 3, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 13 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 13 |
| Avg rating (−2 sell to +2 buy) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.60 | ||
| 2026-08-11 | $-0.65 | $-0.51 | -26.5% |
| 2026-05-12 | $-0.48 | $-0.60 | +20.0% |
| 2026-03-03 | $-0.75 | $-0.59 | -27.1% |
| 2025-11-06 | $-0.65 | $-0.57 | -14.0% |
| 2025-08-06 | $-0.50 | $-0.52 | +3.8% |
| 2025-05-12 | $-0.52 | $-0.66 | +21.2% |
| 2025-03-19 | $-0.84 | $-0.68 | -23.5% |
Valuation Ratios
| Price / Book | 4.23 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | $14.0M | $9.0M | $6.9M |
| Cost of Revenue | $521,000 | $615,000 | $755,000 | 0 | 0 | 0 | 0 | $3.0M |
| Gross Profit | -$521,000 | -$615,000 | -$755,000 | 0 | 0 | $14.0M | $9.0M | $4.0M |
| Research & Development | $6.9M | $8.8M | $6.7M | $14.1M | $23.3M | $23.1M | $129.5M | $174.3M |
| Selling, General & Admin | $866,000 | $1.5M | $4.8M | $11.1M | $13.6M | $19.7M | $33.0M | $43.8M |
| Operating Expenses | $7.7M | $10.3M | $11.5M | $25.2M | $36.9M | $123.5M | $314.8M | $218.1M |
| Operating Income | -$7.7M | -$10.3M | -$12.3M | -$25.2M | -$36.9M | -$109.5M | -$305.8M | -$214.1M |
| EBITDA | -$7.2M | -$9.7M | -$17.0M | -$23.9M | -$36.3M | -$28.0M | -$151.4M | -$209.4M |
| Interest Expense | $141,000 | $106,000 | $38,000 | $10,000 | $5,000 | 0 | 0 | 0 |
| Pre-tax Income | -$7.8M | -$10.4M | -$17.8M | -$24.7M | -$36.9M | -$106.8M | -$293.0M | -$212.4M |
| Income Tax | $39,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$7.8M | -$10.6M | -$17.8M | -$24.7M | -$36.9M | -$106.8M | -$293.0M | -$212.4M |
| EPS | -$7.18 | -$1.84 | -$1.69 | -$2.14 | -$3.09 | -$5.38 | -$5.00 | -$2.43 |
| EPS (Diluted) | -$7.18 | -$1.84 | -$1.69 | -$2.14 | -$3.09 | -$5.38 | -$5.00 | -$2.43 |
| Shares Outstanding (Diluted) | 1.1 M | 5.7 M | 10.1 M | 11.5 M | 12.1 M | 19.8 M | 58.6 M | 87.4 M |
Price
| Price | $19.59 (closing price, November 2, 2026) |
| Market Cap | $2.3B |
| Exchange | NASDAQ |
| Country | US |
Related companies: CLDX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of IMNM: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks